Psychopharmacology and Psychiatry Updates podkast

Naltrexone vs. Topiramate: FDA-Approved vs. Off-Label Options for MAUD

0:00
10:07
Do tyłu o 15 sekund
Do przodu o 15 sekund

In this episode, we explore groundbreaking head-to-head research comparing topiramate and naltrexone for alcohol use disorder, revealing surprising equivalence in effectiveness. Could the off-label option actually be as good as our FDA-approved standard for treating problematic drinking?

Faculty: David Gorelick, M.D.
Host: Richard Seeber, M.D.

Więcej odcinków z kanału "Psychopharmacology and Psychiatry Updates"